Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.87

-2.3%

Dec 5 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robohogs who wrote (5580)	1/29/2002 9:58:43 PM
From: Biomaven	of 52153

Jon, Clarinex took 10% of the plain Claritin market That's a very good showing. Probably helped that they priced it some below Claritin. Of course, given Soltara, it's not entirely clear from SEPR's perspective whether it's a good thing if Clarinex does well or not. <g> SGP's marketing of Claritin was a real demonstration of the power of marketing over substance. Claritin is a pretty marginal drug at the official dose - and at a higher doses you get some sedation. It's interesting how successfully AZN has been fending off generic Prilosec. Makes me wonder if SGP is going to pull something out of its hat to try to delay generic Claritin. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next